Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q2 2018 · 10-Q
Revenue—
Net Income-$1.21M-$1.21MN/M vs Q2 2017 EPS Diluted-$0.03-$0.03N/M vs Q2 2017 Operating Income-$1,428,224N/M Operating Cash Flowderived-$1,164,178N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Jun 30, 2018 · filed Aug 14, 2018 · 45 d after period end